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- 
Transmurai myocardial infarction in dogs produces dener- 
vation of sympathetic nerves in viable myocardium apical 
to the infarct that may be arrhythmogenic. It is unknown 
whether sympathetic denervation occurs in humans. The 
purpose of this study was to use iodine-123.metaiodo- 
benzylguanidine (MIBG), a radiolabeled guanethidine an- 
alog that is actively taken up by sympathetic nerve termi- 
nals, to image noninvasively the cardiac sympathetic nerves 
in patients with and without ventricular arrhythmias after 
myocardiai infarction. 
Results showed that 10 of 12 patients with spontaneous 
ventricular tachyarrhythmias after myocardial infarction 
exhibited regions of thallium-201 uptake indicating viable 
perfused myocardium, with no MIBG uptake. Such a 
finding is consistent with sympathetic denervation. One 
patient had frequent episodes of nonsustained ventricular 
tachycardia induced at exercise testing that was eliminated 
by beta-adrenoceptor blockade. Eleven of the 12 patients 
had ventricular tachycardia induced at electrophysiologic 
study and metoprolol never prevented induction. Sympa- 
thetic denervation was also detected in two of seven postin- 
farction patients without ventricular arrhythmias. Normal 
control subjects had no regions lacking MIBG uptake. 
This study provides evidence that regional sympathetic 
denervation occurs in humans after myocardiai infarction 
and can be detected noninvasively by comparing MIBG and 
thallium-201 images. Although the presence of sympathetic 
denervation may be related to the onset of spontaneous 
ventricular tachyarrhythmias in some patients, it does not 
appear to be related to sustained ventricular tachycardia 
induced at eiectrophysiologic study. 
(J Am Co11 Cardiol1989;14:1519-26) 
- 
Transmural myocardial infarction in dogs produces afferent 
(1) and efferent (2) sympathetic and vagal denervation in 
noninfarcted myocardium apical to the infarct site. This 
viable apical tissue demonstrates denervation supersensitiv- 
ity of refractoriness to norepinephrine and isoproterenol (3) 
and may make the heart more susceptible to the develop- 
ment of arrhythmias (4). 
Until recently. cardiac sympathetic innervation could 
not be assessed noninvasively. Metaiodobenzylguanidine 
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(MIBG) is a guanethidine analog that is taken up by sympa- 
thetic nerve endings (5-7). When labeled with iodine-123, 
MIBG can be used to generate a scintigraphic image of 
efferent sympathetic nervous innervation of the heart (8-14). 
Minardo et al. (11) showed that MIBG images in dogs after 
transmural myocardial infarction reveal areas of myocar- 
dium apical to the infarct that do not take up MIBG but have 
normal perfusion as demonstrated by uptake of thallium-20 1. 
These areas exhibit sympathetic efferent denervation as well 
as supersensitivity to norepinephrine at subsequent electro- 
physiologic testing. 
Because regional sympathetic denervation may play a 
role in the genesis of arrhythmias following myocardial 
infarction in patients, the purpose of this study was to 1) 
determine whether efferent sympathetic denervation occurs 
in patients after myocardial infarction; 2) determine if a 
relation exists between denervation and ventricular arrhyth- 
mias. induced at stress test and electrophysiologic study; 
and 3) test whether beta-adrenoceptor blockade affects these 
arrhythmias. 
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Table 1. Group I: 12 Patients With Arrhythmias 
Case Age 
No. (yr) Ml CABG 
Clinical 
Arrhythmia EPS TMET 24-hr ECG 
Days 
After 
MI Result 
1 82 
2 59 
3 67 
4 48 
5 61 
6 36 
I 62 
8 4-I 
9 62 
10 14 
11 67 
12 48 
Inferior 1958; 
non-Q wave 2/87 
Anterior 1 l/81 
Inferior 2/87 - VT-NS (R) VT-NS VT-NS (R) 
Inferolateral 1980; 
inferior 1981 
Inferior 1982; 
anterior 3/87 
Anterior 3/87 
Inferior 1%8; 
non-Q wave 1974 
Anterior 1977; 
inferior 1984 
Posterolateral 
lo/87 
Inferior 1972; 
non-Q wave 1986 
Inferior 1967 
Inferior 4187 
- VT-S VT-S - 
1982 VF VT-S PVCS 
- VT-S VT-S - 
- VF 
- VT-S 
- VT-S 
1984 VT-S VF PVCS 
- VT-S VT-S No arrhythmia 
- VF VT-S 
1977 VT-S VT-S 
- VF VT-S 
VT-S 
VT-S 
VT-S 
PVCS 
- 
PVC 
PVCs; 
1 VT-NS 
PVC 
PVCS 
22,133 PVC; 
254 VT-NS 
1048 PVC; 
1 VT-NS 
719 PVC 
90 
2,005 
152 
474 PVC; 
2 VT-NS 
2399 PVC; 
2 VT-NS 
1 PVC 
19,107 PVC; 
146 VT-NS 
784 PVC; 
3 VT-NS 
4183 PVC; 
1 VT-NS 
Frequent PVC; 
4 VT-NS 
2,190 
150 
150 
5,ooo 
1,095 
104 
730 
- 
2846 PVC 
3 VT-NS 
7,300 
35 
Apical denervation 
Apical denervation 
Apical t 
posterolateral 
denervation 
Inferoapical 
denervation 
Inferoapical 
denervation 
Apical denervation 
Apicolateral 
denervation 
Inferoapical 
denervation 
Apical denervation 
Apical denervation 
No denervation 
No denervation 
CABG = coronary artery bypass surgery; EPS = electrophysiologic study; MI = myocardial infarction; PVC = premature ventricular complex; Result = 
comparison of MIBG and thallium scans; TMET = treadmill exercise test; VF = ventricular fibrillation; VT-NS = nonsustained ventricular tachycardia; VT-NS 
(R) = repetitive nonsustained ventricular tachycardia; VT-S = sustained ventricular tachycardia; 24-h ECG = 24-h electrocardiographic recording. 
Methods 
Study patients. Twelve men aged 36 to 82 years (mean 59 
2 12.9) referred to Indiana University Medical Center for 
evaluation and treatment of ventricular arrhythmias occur- 
ring later than 1 week after myocardial infarction composed 
group I. Clinical characteristics including arrhythmias are 
listed in Table 1. 
Group ZZ consisted of seven men aged 36 to 63 years 
(mean 56 ? 9.4) who were studied 1 week after myocardial 
infarction and had no known ventricular arrhythmias. Clin- 
Table 2. Group II: Seven Patients Without Arrhythmias* 
Case Age 
No. (yr) MI CABG TMET 24-h ECG 
Days 
After 
MI Result 
13 61 Inferior 3/86 - 
14 57 Posterolateral 1981 - 
15 55 Inferolateral 8188 - 
16 36 Inferior 2/88 - 
17 62 Anterior 12/84 - 
18 60 Inferior 5/88 - 
19 63 Inferior - 
No ventricular 
arrhythmia 
- 
No ventricular 
arrhythmia 
No ventricular 
arrhythmia 
No ventricular 
arrhythmia 
No ventricular 
arrhythmia 
No ventricular 
arrhythmia 
6 PVC 850 Inferior denervation 
41 PVC 2,555 Inferoseptal denervation 
11 PVC 14 No denervation 
1,327 PVC 197 No denervation 
- 1,365 No denervation 
11 PVC 67 No denervation 
643 PVC 923 No denervation 
*Abbreviations as in Table 1. 
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ical characteristics are listed in Table 2. Patients in groups I 
and II were nonrandomly selected on the basis of a previ- 
ously documented myocardial infarction and the presence 
(group I) or absence (group II) of spontaneous ventricular 
tachycardia or ventricular fibrillation. 
Group III consisted of four normal volunteers without 
known arrhythmias, cardiac disease or other medical illness 
who underwent thallium-201 and MIBG imaging. All sub- 
jects gave informed consent for the study before undergoing 
any of the investigations. 
Thallium-201 scintigraphy. Patients initially underwent 
treadmill exercise testing combined with thallium-201 scin- 
tigraphy. One minute before completion of exercise, 2.7 to 
3.3 mCi of thallium-201 was injected intravenously. With use 
of a commercially available gamma camera equipped with a 
low energy all purpose collimator, planar (anterior, 45” left 
anterior oblique and left lateral) images were obtained im- 
mediately after exercise (stress) and 4 h later (redistribu- 
tion). Single photon emission computerized tomographic 
(SPECT) images were acquired during the redistribution 
phase and were reconstructed with commercially available 
software to display tomographic slices along the short, 
vertical long and horizontal long axes. 
Iodine-123-metaiodobenzylguanidine (‘231-MIBG) imag- 
ing. High purity I-123-metaiodobenzylguanidine (1231- 
MIBG) was synthesized according to our previously pub- 
lished methods (15) at a specific activity of 7 to 10 mCi/mg. 
Injected doses of ‘231-MIBG ranged from 4.3 to 5.4 mCi (0.43 
to 0.77 mg of MIBG). identical planar and SPECT views 
were obtained during 1231-MIBG imaging with the same 
gamma camera used for thallium-201 imaging. Images were 
obtained 2 to 4 h after injection of ‘231-MIBG to allow for 
significant clearance of extraneuronal ‘231-MIBG uptake. 
Metaiodobenzylguanidine images were obtained 24 to 72 h 
after thallium imaging. The clinical status of all patients 
remained stable during this time. Two nuclear radiologists 
who did not know the clinical history interpreted the scans. 
Areas of sympathetic denervation were defined as regions 
that demonstrated perfusion on the redistribution thallium 
scan but had no MIBG uptake (that is, MIBG/thallium-201 
mismatch) (Fig. 1). Infarct areas demonstrated no uptake of 
either thallium-201 or MIBG (matched defect). 
Electrophysiologic testing. Patients in group I underwent 
electrophysiologic testing as previously described (16) using 
up to three ventricular extrastimuli while pacing at three 
different cycle lengths from two separate right ventricular 
sites. Sustained ventricular tachycardia was defined as that 
lasting >30 s or requiring termination earlier as a result of 
hemodynamic compromise. Nonsustained ventricular tachy- 
cardia was defined as three or more consecutive premature 
ventricular complexes that self-terminated in <30 s. Repet- 
itive nonsustained ventricular tachycardia was defined as 
frequent episodes of nonsustained ventricular tachycardia 
separated by periods of sinus rhythm, each lasting <5 s. If 
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Figure 1. Schematic illustration of apical sympathetic denervation 
(double arrows) in the setting of an inferior myocardial infarction 
(single arrow) viewed in the vertical long axis of a SPECT image. 
MIBG = I-123-metaiodobenzylguanidine image. TL = thallium-201 
image. 
sustained ventricular tachycardia was electrically inducible, 
15 mg of metoprolol was infused intravenously over 15 min 
and programmed stimulation was repeated. 
A 24 h continuous electrocardiographic (ECG) recording 
was obtained before electrophysiologic study in each pa- 
tient. Quantitative analysis was performed by hand count- 
ing. 
Left ventricular function was determined by ejection 
fraction calculated from two-dimensional echocardiograms 
using Simpson’s rule formula. 
Radionuclide imaging, 24 h ECG recording and, in group 
I patients, electrophysiologic study were performed while 
subjects were receiving no antiarrhythmic or beta- 
adrenoceptor blocking drugs. 
Results 
MIBG-thallium mismatch. The interpretation of both 
blinded observers was concordant in all cases. Ten (83%) of 
the 12 postinfarction patients with ventricular arrhythmias 
(group I) had areas of I-123-metaiodobenzylguanidine 
(MIBG)/thallium-201 mismatch (Fig. 2 to 5). Two (29%) of 
the seven patients without ventricular arrhythmias after 
infarction (group II) demonstrated a region of MIBGl 
thallium-201 mismatch. None of the four group III patients 
without myocardial infarction had regions of MIBG/ 
thallium-201 mismatch. 
Group I patients: ventricular arrhythmias after myocardial 
infarction (Table 1): Nondenervated. Two patients with 
previous inferior myocardial infarction (Patients 11 and 12) 
exhibited matching defects on their thallium-201 and MIBG 
scans. One of these patients underwent imaging 35 days after 
infarction and the other 20 years after infarction. The latter 
also had undergone coronary artery bypass grafting 10 years 
previously. Their clinical arrhythmia was ventricular fibril- 
lation and sustained ventricular tachycardia, respectively, 
and both had sustained ventricular tachycardia induced at 
control electrophysiologic study. Administration of meto- 
pro101 failed to prevent the induction of sustained ventricular 
tachycardia in both cases. 
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Figure 2. Patient 4. SPECT images of patient with an inferior 
myocardial infarction. Note that the apex (arrows) is perfused as 
demonstrated by the thallium-201 (TL) images. The metaiodoben- 
zylguanidine (MIBG) images show a defect in the apex (arrows). 
Images progress from medial (top left) to lateral (bottom right). A = 
anterior; Ao = aorta; LA = left atrium; P = posterior; PA = 
pulmonary artery. 
Twenty-four hour ECG recording in one subject (Patient 
12) showed spontaneous episodes of nonsustained ventricu- 
lar tachycardia of three complexes’ duration. Treadmill 
exercise testing revealed premature ventricular complexes in 
both patients, but no episodes of ventricular tachycardia. 
Group I: Denervated (Table 1). Ten patients exhibited 
defects on their MIBG images that exceeded the defects 
seen on their thallium images; that is, MIBG uptake was 
absent in some areas where thallium uptake was present. 
The reverse was never true. Infarct locations varied, and the 
time from the most recent infarction ranged from 3 months to 
10 years. Two of these patients had previously undergone 
coronary artery bypass grafting. Clinical arrhythmias in- 
cluded cardiac arrest in three, sustained ventricular tachy- 
cardia in six and symptomatic nonsustained ventricular 
tachycardia in one. 
Sustained ventricular tachycardia was induced at control 
electrophysiologic study in 8 of the 10 patients. Seven of 
these patients received intravenous metoprolol, and sus- 
tained ventricular tachycardia was again inducible in all 
seven patients using the same programmed electrical stimu- 
lation sequence. Ventricular fibrillation was induced in one 
patient at the control electrophysiologic study but was 
believed to represent a nonclinical arrhythmia. The patient 
who presented with nonsustained ventricular tachycardia as 
his clinical arrhythmia had only nonsustained ventricular 
tachycardia induced at electrophysiologic study and did not 
receive intravenous metoprolol. 
Twenty-four hour ECG recordings revealed spontaneous 
nonsustained ventricular tachycardia in eight of these ten 
patients. 
Seven of these patients underwent treadmill exercise 
testing. One patient, who had presented with nonsustained 
ventricular tachycardia as his clinical arrhythmia, exhibited 
repetitive nonsustained ventricular tachycardia at control 
exercise testing. At repeat, maximal exercise testing, after 
treatment with 50 mg of metoprolol given orally twice daily, 
no ventricular tachycardia occurred. Metaiodobenzylguani- 
dine and thallium-201 imaging performed in this patient 5 
Figure 3. Same patient. Comparable slices demon- 
strating uptake of thallium-201 (TL) (white arrow) 
but not I-123-metaiodobenzylguanidine (MIBG) 
(black arrow) in the apex in the setting of an inferior 
myocardial infarction. Orientation as in Figure 2. 
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Figure 4. Patient IO. SPECT images from patient with an inferior 
myocardial infarction. Note that the apex (arrows) is perfused as 
demonstrated by the thallium (TL) images. The metaiodobenzyl- 
guanidine images show a defect in the apex. Images progress 
from inferior (top left) to superior (bottom right). R = right; RA = 
right atrium: SVC = superior vena cava; other abbreviations as in 
Figure 2. 
months after infarction revealed a large area of sympathetic 
denervation involving the apex and posterolateral walls. 
Repeat MIBG and thallium-201 imaging 3 months later 
showed a persistent area of denervation. Repeat exercise 
testing in the drug-free state once again induced frequent 
episodes of nonsustained ventricular tachycardia. 
Group II patients: absence of ventricular arrhythmias after 
myocardial infarction (Table 2). Two group II patients 
showed regions with MIBG/thallium-201 mismatch (Patients 
13 and 14). One of them demonstrated lack of MIBG uptake 
in a region with a thallium-201 defect surrounding the infarct 
on stress but reversing on redistribution. None of the group 
II patients exhibited ventricular ectopic activity during ex- 
ercise testing. The two patients with MIBGlthallium-201 
mismatch had 6 and 41 premature ventricular complexes, 
respectively, on 24 h ECG recording. Similar to the group I 
patients with ventricular tachycardia, one group II patient 
showed evidence for sympathetic denervation >2 years after 
infarction (Patient 13) and, conversely, one had matching 
MIBGithallium-201 scans as early as 2 weeks after infarction 
(Patient 15). 
Ejecfion fraction tended to be greater in the patients with 
ventricular arrhythmias (group I) than in those without 
(group II) (38.2 ? 15.1% versus 26.8 + 7.8%; p = 0.059). 
There was no difference in ejection fraction between patients 
with and those without sympathetic denervation (33.7 + 
14.4% versus 37.6 I 14.6%; p = 0.627). 
Group III patients. Four normal volunteers underwent 
thallium-201 and MIBG imaging. All scans exhibited uniform 
Figure 5. Same patient. Comparable slices 
demonstrating uptake of thallium-201 (TL) 
but not I-123-metaiodobenzylguanidine 
(MIBG) in the apex (arrow). Orientation is 
the same as in Figure 4. 
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uptake of thallium-201 and MIBG, revealing no areas of 
mismatch. 
Discussion 
This study reports that myocardial infarction can result in 
mismatch of I-123-metaiodobenzylguanidine (MIBG)/thal- 
lium-201 cardiac images, suggesting interruption of the ef- 
ferent sympathetic nerves to noninfarcted areas of the hu- 
man heart. 
Previous animal findings. The afferent and efferent sym- 
pathetic nerves in the dog appear to be located in the 
subepicardial region (17,18). Efferent fibers carry impulses in 
a base to apex orientation, and afferent fibers in the opposite 
direction. Damage to this region by transmural myocardial 
infarction in the dog has been extensively documented to 
abolish sympathetic tierent and efferent responses in myo- 
cardium apical to the infarct (1+11,19,20). However, the 
relevance of the animal data to similar situations in humans 
has never before been established. The technique described 
here permits noninvasive assessment of the integrity of the 
human cardiac sympathetic nervous system and demon- 
strates, as in the dog, that myocardial infarction produces 
MIBG defects consistent with regional sympathetic dener- 
vation of apical myocardium. Actual proof of denervation 
awaits further investigations similar to the canine studies 
(11) during which the presence of denervation is correlated 
with the MIBG defect. In the dog, denervation is followed by 
denervation supersensitivity (3), which may be arrhyth- 
mogenic (4), and reinnervate 12 to 14 weeks later (11). 
Whether these series of changes also occur in humans 
needs to be determined. Persistent MIBG defects in 12 of the 
present patients (3 to 166 months after myocardial infarction) 
suggests that reinnervation is not an obligatory sequela. 
Patients 11, 12 and 15 through 19, without evidence of 
sympathetic denervation, may have undergone reinnerva- 
tion. What factors determine reinnervation also need to be 
established. 
MIBG uptake physiology. Norepinephrine and MIBG 
share similar uptake and storage mechanisms in sympathetic 
nerve terminals. Both are sequestered by the neuronal 
uptake-one system. Pretreatment with desmethylimipramine 
or cocaine (7) (uptake-one inhibitors), and reserpine (14) (a 
blocker of norepinephrine and guanethidine uptake into 
adrenergic nerve storage vesicles) inhibit MIBG and norep- 
inephrine uptake in animals. Cardiac intraneuronal storage 
of MIBG remains constant during the initial 6 h after 
injection, whereas extraneuronal accumulation decreases 
rapidly during that time (14). High levels of circulating 
catecholamines, as seen in patients with pheochromocy- 
toma, inhibit cardiac accumulation of MIBG suggesting 
competitive uptake of norepinephrine and MIBG (21,22). 
Clinical significance. The present study provides evi- 
dence that sympathetic denervation occurs after myocardial 
infarction but does not establish the importance of such a 
finding. The relatively small number of patients and the wide 
range in the frequency of spontaneous ventricular arrhyth- 
mia in the group of patients with sympathetic denervation 
preclude establishing a causal relation with sympathetic 
denervation. Exercise testing is well known to be an insen- 
sitive provocative test for the induction of ventricular tachy- 
cardia. This remains true, despite the presence of sympa- 
thetic denervation. We had speculated that exercise testing, 
by causing systemic and cardiac catecholamine release, 
might increase the dispersion of ventricular refractoriness 
because of the presence of denervated sites and lead to 
ventricular arrhythmias. This phenomenon may have been 
operative in one patient in whom beta-adrenergic blockade 
did prevent exercise induction of repetitive nonsustained 
ventricular tachycardia. 
That beta-adrenoceptor blockade did not prevent the 
electrical induction of ventricular arrhythmias is not surpris- 
ing and is consistent with earlier reports (23,24). Pro- 
grammed electrical stimulation is an artificial means of 
arrhythmia induction and may circumvent modulation by the 
autonomic nervous system. Arrhythmias that depend on 
critical degrees of autonomic tone for spontaneous onset 
may still be electrically inducible, and not affected by 
beta-adrenoceptor blocking drugs. 
Thus, the importance of regional sympathetic denerva- 
tion demonstrated by MIBGlthallium-201 mismatch in pa- 
tients after myocardial infarction is not known and its 
relation to the genesis of ventricular tachyarrhythmias un- 
certain. The role of both alpha- and beta-stimulation and 
blockade in precipitating, preventing or predisposing to the 
genesis of ischemic arrhythmias in animals is well estab- 
lished (25,26). In humans, several studies (27,28) have 
proved the protective effects of beta-adrenoceptor blockade 
and preliminary data (29) support the protective action of 
surgical left stellate ganglion interruption. The latter pro- 
duces denervation that may be protective because, in con- 
trast to the regional denervation after infarction, it creates 
denervation and resultant electrophysiologic homogeneity 
involving large areas of myocardium. 
Therefore, it is clear that the sympathetic nervous system 
affects spontaneous arrhythmia development in patients with 
coronary artery disease based on the results of interventions 
that block sympathetic effects. The converse-that is, stim- 
ulating the sympathetic nervous system and provoking ven- 
tricular arrhythmias-is less clearly established. It is quite 
possible that classical provocation using electrophysiologic 
study or treadmill exercise test may not be appropriate. 
Finer or more specific probes, for example, intravenous 
infusion of catecholamines in patients with sympathetic 
denervation, may be necessary. In addition, it is quite 
possible that regional sympathetic denervation is arrhyth- 
mogenic only during the acute ischemic event, which begins 
in dogs within minutes of the onset of ischemia (2), and that 
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what we are witnessing in these patients is simply the 
residual of the initial lesion. 
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